Compare Endeavour Silver Corp (EXK) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Incyte Corporation — how do they compare? Endeavour Silver Corp trades at $8.65 (market cap $2.54B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 9× Endeavour Silver Corp's market cap, and Incyte Corporation is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and Incyte Corporation for 33 Days on average.
| EXK | INCY | |
|---|---|---|
Market Cap | $2.54B | $22.85B |
Volume | 7,077,330 | 1,927,029 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $129.93 |
52-Week Low | $7.07 | $83.80 |
Typical Hold Time | 25 Days | 33 Days |
Enterprise Value | $2.54B | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.57, up 3.0% today, amid a bearish technical signal from moving averages but with neutral oscillators. The company reported a net loss of $119.1 million in 2025, though 2026 projections show a turnaround to a $66 million net profit. Recent news highlights operational progress at the Terronera and Kolpa mines, alongside temporary disruptions now resolved.
The outlook is mixed: strong analyst buy consensus (78.57%) and projected 2026 profitability support upside, but high P/E of 42.85 and operational risks from mine blockades pose challenges. Investment appeal hinges on execution of growth projects and silver price stability.
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
